文献速递心律失常

ENGAGE AF-TIMI 48随机临床试验中用于心房颤动净临床结局的新型风险预测评分

A novel risk prediction score in atrial fibrillation for a net clinical outcome from the ENGAGE AF-TIMI 48 randomized clinical trial.
PubMed 文献 · Eur Heart J · 2017-01-01

基于ENGAGE AF-TIMI 48试验中2898例未使用维生素K拮抗剂(VKA)的心房颤动(AF)患者,开发了预测严重净临床结局(NCO)的17分TIMI-AF评分。华法林组低、中、高危年化事件率分别为3.5%、9.9%、20.8%;高剂量和低剂量依度沙班较华法林在高危和中危组显示治疗获益,低危组获益相当。

要点

  • TIMI-AF评分可预测AF患者严重净临床结局,模型C指数为0.693。
  • 华法林组低、中、高危年化事件率分别为3.5%、9.9%、20.8%。
  • 高剂量和低剂量依度沙班较高危和中危组华法林有治疗获益,低危组获益相当。

核心结论

  • 在未使用VKA的AF患者中,TIMI-AF评分有助于预测不良复合结局,并通过识别NOAC与VKA的差异化临床获益来指导抗凝治疗选择。

研究设计与样本

  • ENGAGE AF-TIMI 48是一项随机临床试验,比较依度沙班与华法林在21105例AF患者中的效果。
  • 从华法林组未使用VKA的患者中,采用Cox比例风险模型识别与严重净临床结局(NCO)相关的因素,并开发整数风险评分。
  • 通过C指数评估性能,采用bootstrapping进行验证;按三个评分类别和治疗组进行Kaplan-Meier分析。

主要发现

  • 中位随访2.7年,2898例患者中发生457例NCO事件,总人时为7549.5年(6.05%/年)。
  • 风险预测模型(C=0.693)转化为17分整数评分,华法林组低、中、高危类别的年化事件率分别为3.5%、9.9%、20.8%。
  • 高剂量和低剂量依度沙班较华法林在高危和中危组显示治疗获益,低危组获益相当(交互作用P值分别为0.008和0.014)。

关键数值与推荐

  • TIMI-AF评分为17分制,模型C指数为0.693。
  • 华法林组低危年化事件率为3.5%,中危为9.9%,高危为20.8%。
  • 高剂量和低剂量依度沙班与华法林比较的交互作用P值分别为0.008和0.014。

临床怎么用

  • TIMI-AF评分可辅助预测未使用VKA的AF患者的不良复合结局,并指导NOAC或VKA的选择。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS: The choice between initiating a non-vitamin K antagonist oral anticoagulant (NOAC) and a vitamin K antagonist (VKA) in patients with atrial fibrillation (AF) may be challenging. To assist in this decision, we developed a risk score to identify patients for whom a therapeutic benefit of NOACs over VKA is predicted. METHODS AND RESULTS: ENGAGE AF-TIMI 48 was a randomized clinical trial of edoxaban vs. warfarin in 21 105 patients with AF. Cox proportional hazard models identified factors associated with a serious net clinical outcome (NCO) of disabling stroke, life-threatening bleeding, and all-cause mortality in VKA naïve patients from the warfarin arm. These were used to develop an integer risk score. Performance was assessed by C-indices and validation by bootstrapping. Kaplan-Meier analyses were stratified by three score categories and treatment arm. Over a median of 2.7 years, 457 NCO events occurred in 2898 patients with a total person-time of 7549.5 years (6.05%/year). The risk prediction model (C = 0.693) for the NCO was translated into a 17-point integer score, with annualized event rates for the low, intermediate, and high-risk categories in the warfarin arm of 3.5%, 9.9%, and 20.8%, respectively. Therapeutic benefit of higher- and lower-dose edoxaban over warfarin was demonstrated in the high- and intermediate-risk, with equal benefit in the low-risk categories (P-interaction 0.008 and 0.014, respectively). CONCLUSION: In VKA naive patients with AF, the TIMI-AF score can assist in the prediction of a poor composite outcome and guide selection of anticoagulant therapy by identifying a differential clinical benefit with a NOAC or VKA.

来源:Eur Heart J,查看原文。版权归原作者所有。

引用

  1. Fanola CL, Giugliano RP, Ruff CT, et al. A novel risk prediction score in atrial fibrillation for a net clinical outcome from the ENGAGE AF-TIMI 48 randomized clinical trial. Eur Heart J. 2017. PMID: 28064150. doi:10.1093/eurheartj/ehw565

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。